The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a … Read more
Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant’s bundle of recent acquisitions in a Monday interview with CNBC’s Jim Cramer, and indicated the company is in a transformative stage. “We are writing the next chapter of this company,” Boerner said. “And we’ve got real financial strength that has enabled us to go and actually … Read more
CNBC’s Jim Cramer on Friday pointed out the number of biopharma mergers and acquisitions that have closed or been announced over the last few months. He told investors to keep an eye on these moves in advance of the JPMorgan health care conference next week. “I know that drug companies are tough to own in … Read more
Our 10 things to watch Tuesday, Dec. 26 1. Stocks rose slightly to kick off the final trading week of the year, as longer-dated bonds pull back slightly. Santa Clause rally in the making? We closed out last week with the S & P Short Range Oscillator at 6.54%, which means we are still technically … Read more
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock popped more than 47% on the news Friday morning, hitting around $317 a share. Bristol Myers Squibb shares rose more than 2%. The deal will help expand Bristol Myers’ drug … Read more
